Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TREATLIVMETS

Financiado

Cerrado

Treating Liver Metastasis

Liver metastases commonly develop in up to 50% of patients with various cancer types. The most common cancer that metastasizes to the liver is colorectal cancer (CRC). At least 25% of CRC patients develop colorectal liver metastas... ver más

30/06/2030

UNI WUERZBURG

10M€

Presupuesto del proyecto: 10M€

Líder del proyecto

JULIUSMAXIMILIANSUNIVERSITAT WURZBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-07-01

ERC-2023-SyG: ERC Synergy Grants Objective:The aim is to provide support for a small group of two to four Principal Investigators to...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UNI WUERZBURG

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC2019-006860-1 Ensayo clínico fase I/II: nuevo enfoque terapéutico para el... 1K€ Cerrado

GDCOLCA Understanding gamma delta T cells in colon cancer metastasis 195K€ Cerrado

MULTIR MULti-Tumour based prediction and manipulation of Immune Res... 9M€ Cerrado

NR2F6-AIM NR2F6 Blockade as Adoptive Immune Cell Therapy for Metastati... Cerrado

PID2020-116393RB-I00 NUEVA GENERACION DE INMUNOTERAPIAS CONTRA CANCER BASADAS EN... 257K€ Cerrado

EPIC Enabling Precision Immuno oncology in Colorectal cancer 2M€ Cerrado

Duración del proyecto: 71 meses Fecha Inicio: 2024-07-01
Fecha Fin: 2030-06-30

Líder del proyecto

JULIUSMAXIMILIANSUNIVERSITAT WURZBURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 10M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Liver metastases commonly develop in up to 50% of patients with various cancer types. The most common cancer that metastasizes to the liver is colorectal cancer (CRC). At least 25% of CRC patients develop colorectal liver metastases (CRLM) during their illness. CRLM represent the major unmet clinical need for this malignancy, as the 5-year survival rate of patients with unresectable disease does not exceed 2%. New therapies that promote antitumor immunity have been recently developed, mostly focusing on enhancing T cell responses. Although these therapies have led to unprecedented successes, only a minority of patients benefit from these treatments, highlighting the need to identify new cells and molecules that could be exploited in next generation immunotherapies. Given the crucial role of innate immune responses in immunity, targeting these responses opens up new possibilities for tumour control. We hypothesize that the immunotherapy of liver metastases can be significantly improved through harnessing the biology of innate lymphoid cells (ILC), such as Natural Killer (NK) cells and ILC1s, and myeloid cells such as macrophages and DCs. Our team brings together experts in the biology of tissue-resident myeloid (Ginhoux, PI4) and lymphoid (Gasteiger, cPI) cells, in liver immunology (Fumagalli, PI3), and in the development of novel immunotherapeutic strategies that modulate immune cells in the fight against cancer (Vivier, PI2). By combining cutting-edge single cell and spatial transcriptomics of human patient samples with cross-species analyses in advanced genetic mouse models, we aim (1) to identify cellular interactions defining the metastatic tumor microenvironment across murine and human tissue-specimens, (2) to investigate immune cell functions regulating metastatic disease using a unique combination of advanced genetic mouse and human tissue models, and (3) to harness the anti-tumoral functions of innate immune cells via next generation cell engagers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores